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Several RNA ligands that bind to feline immunodeficiency virus (FIV) reverse
transcriptase (RT) were selected by Systematic Evolution of Ligands by
Exponential Enrichment (SELEX) with recombinant FIV RT. Two of these
ligands, F20 #53, and F18 #60 were potent inhibitors of recombinant FIV RT.
Inhibition of RT was competitive with respect to template-primer and
noncompetitive with respect to deoxyribonucleoside 5'-triphosphate substrates.
SELEX ligand F20 #53 inhibited FIV derived from virus better than recombinant
RT. In contrast, SELEX ligand FIB #60 was less inhibitory with virion RT as
compared to recombinant RT. SELEX ligand F20 #53 was also more inhibitory
in reactions with heteropolymeric templates than in reactions with
homopolymeric template. Ligand F20 #53 also inhibited RT from a mutant of
FIV resistant to 3'-azido-3'-deoxythymidine (AZT).
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General Introduction
Human immunodeficiency virus 1 (HIV-1) is an RNA virus that belongs to
the lentivirus family of non-oncogenic, cytopathic retroviruses (9). HIV-1 has
properties

similar

to

prototypic

animal

lentiviruses

including

simian

immunodeficiency virus and feline immunodeficiency virus (FIV) which infect
rhesus macaques and cats, respectively. These animal models may prove useful
in the understanding and the treatment of acquired immunodeficiency
syndrome (AIDS) (10).

Antiviral agents are usually targeted against an enzyme or other viral
component that is instrumental in replication of the virus. Current efforts in
AIDS chemotherapy are focused on interruption of the virus life cycle by
inhibiting reverse transcriptase (RT), viral protease, or other viral proteins (35).
However in clinical treatment of patients there is a rapid emergence of
resistance to the drugs that inhibit RT (35). Kaplan et al. have also found viral
resistance to protease therapy in vitro (15). This rapid emergence of drug
resistance makes new strategies for drug design important.

Systematic

Evolution of Ligands by Exponential enrichment (SELEX) is a novel approach
that may provide strategies to combat resistance (46). This process rapidly
selects for ligands which have a high affinity for target enzymes. The purpose
of this project was to characterize SELEX ligands which had been selected to
bind to FIV RT. In order to study the modes of inhibition of RT by SELEX
ligands, assays to be developed that utilize natural FIV RNA and DNA templates.

FELINE IMMUNODEFICIENCY VIRUS
Feline immunodeficiency virus is a lentivirus that has been shown to
cause an AIDS-like syndrome in cats. This system provides a useful animal
model for the study of AIDS (1, 29).

The FIV system possesses economical
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and practical advantages over other animal models, such as the low cost of
animal care, ease of in vivo studies, and the safety of working with a virus that
does not infect humans (1, 10, 29).

Pathogenesis.

Like HIV-1 infection of humans, FIV infection of cats can be

characterized by a series of five stages. The five stages for FIV infection are:
acute infection, asymptomatic carrier, persistent generalized lymphadenopathy,
AIDS related complex, and AIDS (28).

The primary phase of the FIV infection is characterized by variable
degrees of fever, neutropenia, and generalized lymphadenopathy.

After

disappearance of the early clinical signs of disease, experimentally-infected cats
enter a lengthy period of virus latency (no clinical signs of disease manifested)
during which FIV can still be isolated from the blood. The third stage of
infection is equivalent to the persistent generalized lymphadenopathy stage in
HIV-1 infected humans. This stage is characterized by vague signs of disease in
the absence of obvious infection. The fourth stage is reminiscent of the AIDS
related complex (ARC) in humans. Cats with ARC-like illness have chronic
secondary infections at one or more body sites. If the cat survives stage four
(fewer than 10% do) then the cats exhibit a clinical picture that can be defined
as AIDS-like. Cats with AIDS-like illness, similar to their human counterparts,
often have weight loss (>20% lost) opportunistic infections in multiple body
sites, and most are anemic and leukopenic (28).

Life cycle. The life cycle of FIV is typical of a retrovirus. Following attachment
and entry into a cell, one or both copies of RNA are converted to doublestranded DNA by RT and this DNA is integrated into the hosts genome by
another virus encoded-enzyme, integrase. This integrated viral DNA is called
a provirus.

The provirus is transcribed by cellular DNA-dependent RNA

polymerases to generate structural genes, {gag, po/ and en\/} and full length
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Figure 1. The life cycle of a retrovirus.
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RNA copies which are used as genomes for progeny virus (Fig 1). Viral gene
expression requires the action of regulatory proteins such as Rev and Tat, which
controls expression of viral genes. The proviral DNA remains a permanent
component of the host cell genome and is passed to all daughter cells (45).

There are many points in the life cycle that offer targets for
chemotherapy. Approaches to HIV-1 therapy have targeted a number of these,
including attachment, enzymes such as RT, and protease (35), and regulatory
the proteins, such as Tat and Rev (12).

The most successful target for AIDS therapy has been RT. All of the
drugs that have been approved for AIDS therapy in humans target this enzyme.
These include 3'- azido-3'-deoxythymidine, (AZT), 2',3'-dideoxyinosine (ddl),
2'3'-dideoxycytidine (ddC), and 2',3'-dideoxy-2',3'-didehydrothymidine (d4T).
(35, 37, 42). These nucleoside analogues have modifications at the 3' position
on the deoxyribose. Incorporation of these analogues blocks 5'->3' elongation
during polymerization and result in chain termination (31).

Biochemical features of RT.

North et al. have purified and extensively

characterized the FIV RT. FIV RT has been shown to be similar to HIV-1 RT in
physical properties and in catalytic functions (22, 23, 25,). FIV RT, like HIV-1 RT
has three catalytic functions. It has RNA-dependent DNA polymerase, DNAdependent DNA polymerase, and RNase H activities (7, 34). The FIV and HIV-1
RTs have a similar requirement for IVIg^+ and similar template specificities. The
p61-p55 heterodimer that is observed with HIV-1 RT is similar to that of the FIV
RT. The RT activity of FIV, like HIV-1, is comprised of a heterodimer of two
subunits which have common amino-termini (8). The larger subunit contains
the RNase H domain of RT.

The genes encoding RTs of FIV and HIV-1 also exhibit considerable
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sequence homology. When the predicted amino acid sequence of FIV RT was
compared to that of HIV-1 RT, a 60% identity was observed (26, 44). These
similarities make FIV RT an attractive model for the study of RT-targeted therapy
of human AIDS.

Kinetic mechanism of RT activity. RT catalyzes the synthesis of DNA via an
ordered kinetic mechanism in which template-primer binds to the enzyme
before the first 2'-deoxynucleoside 5'-triphosphate is used for primer elongation
(31). Phosphodiester bond formation proceeds with inversion of configuration
at the «-phosphorus, indicating that the 3'-hydroxyl group of the primer
terminus attacks the a-phosphorus of the 2'-deoxynucioside-5'-triphosphate
substrate without intervening formation of a covalent enzyme intermediate (31).

The steady-state and pre-steady-state kinetics of incorporation of
nucleotides and nucleotide analogues into a defined RNA template sequence
primed with DNA has been examined. The kinetic mechanism that explains the
potent inhibition by chain terminating nucleotide analogues such as AZTTP,
ddATP and ddCTP has been determined. The mechanism of AZTMP proceeds
as follows; The steady state rate of AZTMP incorporation into the 3'-primer
terminus is limited by the rate of dissociation of the chain-terminated template
primer from the enzyme. This slow rate of dissociation leads to the steady-state
accumulation of RT chain-terminated template-primer complex and results in
potent inhibition of the enzyme (31). Inhibition constants have been determined
for several nucleotide analogues, such as, ddATP, and ddCTP, which act by the
same mechanism as AZTTP for HIV-1 RT (5).

North et al. have shown substantial similarities in the kinetic constants for
the inhibition of HIV-1 RT and FIV RT by nucleotide analogues, including, 2',3'dideoxythymidine 5'-triphosphate (ddTTP), AZTTP and 2',3'-dideoxy-2',3'didehydrothymidine 5'-triphosphate (D4TTP) (6, 22, 24, 25). The nucleotide
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analogues were all competitive with respect to variable substrate concentration.
Inhibition constants for these nucleotide analogues with FIV RT and HIV-1 RT
are given in Table 1.
Table 1. Inhibition of FIV RT and HIV-1 RT by nucleotide analogues*.

Inhibitor

Mean K. ± SD fnM)
FIV
HIV

Mean IC/IC ratio
FIV
HIV

AZTTP
dTTP
D4TTP

6.2±1.2
6.7±3.3
1.8±0.7

0.0010
0.0020
0.0005

6.5±1.8
5.9±4.2
8.3±0.8

0.0011
0.0010
0.0014

^values are from North et al. (6, 22, 24).
Inhibition constants for a non-nucleotide analog, phosphonoformic acid
(PFA) have also been determined. PFA is an antiviral drug that inhibits DNA
polymerases, including RT, by blocking the pyrophosphate exit site (40). PFA
has been found to be a noncompetitive inhibitor of HIV-1 and FIV RTs with
respect to a variable substrate concentration, and it yields similar inhibition
constants with these two enzymes (24).

In order to compare activities of FIV and HIV-1 RT further, North et al.
have examined template specificities which are summarized in Table 2. Both
enzymes are able to utilize poly(rA)-oligo(dT)io, poly(rl)-oligo(dC)io and poly(rC)oligo(dG)io- Both enzymes fail to utilize poly(rU)-oligo(dA)io, and poly(rG)oligo(dC )io. The two most effective template-primers are poly(rA)-oligo(dT)io,
and poly(rl)-oligo(dC)io (23).
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Table 2. Template specificity of FIV and HIV RT*.

Template

FIV

HIV

% relative activity ± SD

poly(rA)-oligo(dT)io
poly(rU)-oligo(dA)io
poiy(rC)-oligo(dG)io
poly(rG)-oligo(dC)io
poly(rl)-oligo(dC)io

100
0.1
46 ± 4
0.34 ± 0.6
109 ± 7.8

100
0.29
15 ± 1.5
0.16 ± 0.1
76 ± 1.8

* Values are from North et al (23).

The characterization of these templates has allowed studies of ddCTP,
ddGTP, AZTTP, ddTTP, and PFA. These homopolymeric templates do not allow
the study of dATP analogues such as ddATP. However, Cronn et al. and North
et. al have studied heteropolymeric templates such as M13 and 0X174, in order
to study ddATP (7, 25). The activity of FIV RT with these DNA templates was
only 10-20% of that obtained with poly(rA)-oligo(dT )io as template primers.
None of the heteropolymeric RNA templates tested were efficiently used by FIV
RT.
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DRUG RESISTANCE
Drug resistance is a limiting factor in the treatment of AIDS. AZT was the
first drug approved and used for treatment of AIDS (21), and clinical isolates of
HIV-1 that are resistant to AZT are detected in patients treated six months or
longer with AZT (17, 36). Subsequently, mutants of HIV-1 resistant to ddl and
ddC have been reported (13, 35, 43 ). Mutants resistant to several other
inhibitors such as ddGTP, (30) and protease inhibitors (15, 27, 35) have been
selected in vitro.

It is likely that resistance will arise with most, if not all,

therapeutic approaches.

Resistance of HIV-1 to AZT, is due to mutations which map in the pol
gene (35). Similarly, resistance to other drugs such as ddl and ddC, have also
been mapped in the pol gene of HIV-1 (35). Our lab was the first to report the
selection of an AZT-resisant mutant retrovirus in a cell culture system (32). As
in HIV-1, AZT-resistant mutants of FIV have mutations in poi. FIV systems are
more versatile then HIV-1 systems for the study of drug resistance because FIV
mutants are selected more easily then HIV-1 mutants (35). FIV also is a safer
virus to work with than HIV-1. These features make FIV an attractive model for
studies of resistance for AIDS therapy.

Many strategies to combat drug resistance have been proposed. The
major focus is on combination chemotherapy. However, even with the
combination of AZT and ddl, or ddC resistant mutants of FIV and HIV-1 arise
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(11, 41, 49)

Therefore it is desirable to find drugs or strategies to minimize

resistance. SELEX is a novel approach which may offer an immediate strategy
to combat resistance.

SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT

SELEX is a novel method to rapidly select preferred binding ligands from
a population of random RNA oligonucleotides. Inherent in the SELEX technique
is the specificity of the RNA to the target enzyme (46). Another important
advantage is that RNA may be less cytotoxic than the traditional nucleoside
analogues, which are cytotoxic at high doses.

The SELEX method relies on the mechanism that is usually associated
with evolution, that is, variation, selection, and replication (46). An overview of
this procedure is given in Figure 2. First, a pool of RNAs that are completely
randomized at specific positions are subjected to selection for binding to a
target, in this case to purified recombinant FIV RT on nitrocellulose filters.
Second, the selected RNAs are eluted and converted back to DNA by reverse
transcription, and are amplified as double-stranded DNA by PGR. This DNA is
then used for in wfro transcription by T7 RNA polymerase The resulting DNA is
enriched for those sequences which bind FIV RT. The selected RNA is then
used to begin the next cycle.

More stringent conditions can be used in

subsequent cycles to select the ligands that bind with greatest affinity.
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fandomized template construction
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Figure 2. An overview of the SELEX selection procedure. (Starting at the top,
going cloclcwise) Randomized template construction (46).

In vttro transcilpllai of

the pool of oligonucleotides. Binding of oligonucleotide to target protein
resulting in an enriched RNA population. cDNA synthesis by reverse
transcriptase. Second strand synthesis and polymerase chain reaction (PCR)
amplification.

In vttio transcrlpfton to begin the next round of selection (46).
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This approach has been employed to develop inhibitors of HIV-1 RT (47).
The RNA ligands, although not kineticaily characterized, have been shown to
inhibit HIV RT specifically, and not RTs from avian myoblastosis virus, Maloney
murine leukemia virus, or HIV type 2 (47) A gel-based assay was used in those
studies to measures concentrations which inhibit RT activity by 50 % (ICgo). The
IC50 for inhibition of HIV-1 RT by the RNA ligand was approximately 100 nM
(47). In a collaboration with Dr. Larry Gold's lab (University of Colorado), SELEX
ligands have been made that inhibit the FIV RT (3).

Selection of ligands that bind FIV-RT. High affinity ligands were selected from
an RNA repertoire containing 10^"* unique species with a 40 base long random
RNA sequence. These selections were carried out by Hang Chen and Larry
Gold, Univerisity Colorado. The first ten rounds of selection were performed by
nitrocellulose filter partitioning. The last eight rounds were performed by native
gel shift assays. After 18 rounds of selection, the binding affinity of the
selected RNA pool could not be further improved by continued selection. The
FIV RT binding affinity of RNA from the eighteenth round of selection (Kd 7.7
nM) was at least 10^-fold higher than that of the starting repertoire (Fig 3) (3).

RNA sequences were obtained from eighty clones derived from the
eighteenth round of selection and these were analyzed by an RNA folding
algorithm.
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Figure 3. Binding of RNA from indicated rounds of SELEX to FIV RT. Open
circles represent the starting pool of random RNA, Kd too high for accurate
determination. Open squares represents RNA from round six, Kd too high for
accurate determination. Closed circles represents round 10 with a Kd of >100.
Closed squares represent round 14 with a Kd of 13.6. Open triangles, round 16,
Kd is 8.7. Closed triangles represent round 18 with a Kd of 7.7 (3).
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The selected RNA molecules fell Into three major classes (Fig 4){3). Class I
molecules form stem-loop structures or stem-loops with an internal bulge, and
contain two U-tract consensus sequences present in the region predicted to be
single stranded. Three subsets of class I ligands also have an ACG consensus
in the loop. Class II consists of three subsets of species which could form stemloops with internal bulges. Class III are A-rich and appear to be unstructured as
predicted by the RNA folding program (50).

Seven representatives of the eighty FIV-specific ligands were obtained
for further studies. A major goal of this work was to characterize the inhibition
of FIV RT by those seven SELEX ligands.
ENDOGENOUS TEMPLATES
As will be discussed below, the inhibition of FIV RT by SELEX ligands is
competitive with respect to template-primer. This is in contrast to the existing
antiviral nucleoside analogues, whose 5'-triphosphates compete with a dNTP
substrate.

Virtually all work with RT has been with homopolymeric RNA

templates, which has been adequate for studies of the nucleotide analogues.
However, for the study of SELEX ligands that compete with template-primer for
binding to RT (3), more biologically relevant, heteropolymeric templates are
needed. There is very little information available on use of heteropolymeric
templates for kinetic studies of RT. Characterization of SELEX ligands with such
template-primer systems requires development of new assay systems for FIV RT
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In the past, only a few attempts have been made to use heteropolymeric
templates.

DNA from phages 0X174 and Ml3 are two heteropolymeric

templates that have been used in the kinetic studies of FIV RT (7, 25). RT had
somewhat lower activities with these templates than with the standard
homopolymeric template,
heteropolymeric

RNA

poly(rA)-oligo(dT )io (7, 25). Attempts to use

templates,

including

23S

rRNA

primed

with

oligodeoxyribonucleotides, and poly(A)+mRNA primed with oligo(dT) were
unsuccessful due to the low activities of RT [less than 2% of that with poly(rA)oligo(dT)io] with these templates (7).

Endogenous RNA and DNA templates have been made for some studies
of HIV-1 RT (16, 31). Reardon used short oligonucleotides approximately 50
bases long in order to kinetically analyze the RNA-dependent and DNAdependent activities of HIV-1 RT (31). Klarman et al. have made substantially
larger templates, approximately 1.6 kb in length, in order to study templatedirected pausing of DNA synthesis with HIV-1 RT (16). These authors found
that certain sequences of HIV-1 RNA and DNA contain strong pause and stop
sites for polymerization in vitro. This may explain why some template-primer
systems are not suitable for kinetic studies of FIV RT.

Klarman et al. also

showed that RT dissociates from the primer template at some pause sites and
remains bound at others. These data suggest that when designing endogenous
templates care has to be taken to find sequences that don't contain strong
pause sites (16).
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All of the previous work that has been done with endogenous template
systems has focused on studies of reaction mechanisms or the fidelity and
procestivity of RT (16, 31). There have been no previous studies of ligands that
compete with the template-primer binding site on RT. A major goal of this work
is develop and characterize endogenous templates that can be used in studies
of RT-targeted antivirals, including SELEX ligands.
GOALS

The goals of this study were to evaluate seven SELEX ligands as
inhibitors of FIV RT and study the kinetics of inhibition by the ligands that were
the most potent inhibitors.
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MATERIALS AND METHODS
MATERIALS
Enzymes.

Recombinant FIV RT was purified by a method that has been

developed by North, et al., (25). Wild-type and AZTTP-resistant FIV RTs were
also purified from virions by a procedure described in North, et al. (23). T7 RNA
polymerase, human placenta RNase inhibitor, and RNase-free RQ1 DNase were
purchased from Promaga, Madison Wl. Thermusaquat'cusDHA polymerase was
purchased from Perkin Elmer Cetus, Norwalk CT.

Chemicals. Diethylpyrocarbonate (DEPC), phosphonoformic acid (PFA), 2',3'dideoxycytidine 5'-triphosphate (ddCTP), and Triton X-100 were purchased from
Sigma Chemical CO. St Louis, MO. AZTTP, the 5'-triphosphate of AZT was
provided by Wayne Miller, of Burroughs Wellcome Co., Research Triangle Park,
NC. Poly(rA)-oligo(dT )io, and Poly(rl)-oligo(dC)i2.i8 were purchased form
Pharmacia LKB, Piscataway, N.J. [Methyl-^H]d'TTP, and [5,-5'-^H]dCTP were
obtained from Dupont-New England Nuclear, Boston MA. Geneamp PCR core
reagents were purchased from Perkin Elmer Cetus, Norwalk, CT.

All other

chemicals were reagent grade or better.

Preparation of SELEX Uganctë
RNase free environment. All reagent and equipment were treated with DEPC
or baked at 100 °C whenever possible to ensure that RNase-free materials were
used.
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PCR Amplification.

Amplification of DNAs expressing SELEX ligands were

performed using a Perkin Elmer DNA thermocycler 410. The cassette to be
amplified (Fig 5) had the following sequence; 5'-GGGAGGAUGUUUUCUCAGACCGUAA-N40-UUGCAGGAUCGUGAAGUAGGAUCCGGG-3'where N40 represents
the randomized portion of the SELEX ligand. The 5'-end is primed with primer
designated

as

CH2

(5'-CCCAGCTTAATACGACTCACTATAGGGAGGATAT-

TTTCTCAGACC-3') and the 3' end is primed with primer designated as CH3 (5'CCCGGCTCCTAGTTCACGATGCTGCAA-3')- Each 100 ^1 reaction contained 10
mM Tris-HCI, pH 8.4, 50 mM KCI, 0.75 mM MgClj, 0.05 mg/ml bovine serum
albumin, 1 mM of each dCTP, dATP, dGTP, and dTTP (dNTP), 0.25 pmoles/jul of
each primer CH2 and CH3, and 0.025 U/; j 1 Taq DNA polymerase. The PCR
amplification was run for 25 cycles. Each cycle consisted of 94°C for 30 seconds
for denaturation, 54°C for 20 seconds for annealing, and 72°C for 90 seconds for
elongation (33). The DNA from the PCR amplification was used directly for in vitro
transcription.

In WfrD transcription. RNA ligands were transcribed from the amplified DNA in
vitro. Reactions were run in a total volume of 100 pi\ that contained 40 mM TrisHCI, pH 8.0, 12 mM MgClg, 5 mM dithiothreitol, 1 mM spermidine, 20% W/V
polyehtylene glycol (MW 8000), 0.01% V/V Triton X-100, 0.2 mM each of CTP,
ATP, GTP, and UTP, 20U RNase inhibitor RQ1, 100 U T7 RNA polymerase, and
25^1 (approximately 700 pM) of PCR product (20). The reaction was run at 37 °C
for four hours.
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A. IN WRO CASSETTE.

GCTAATACGACTCACTATAGGGATAUUUUCUCAGACCGUAA-N^-UUGCAGCAUCGUGAACUAGGAUCCGGG-3'
3'-AACGTCGTAGCAC TTGATCCTAGG CCC-5'

B. SELECTED RNA LIGANDS (ONLY THE VARIABLE REGION SHOWN)
F20TH #60 5'-GUACCGAAUGUGCUUUUGGCCGAUUUUUGGCCCCUGCAG-3' Kd=1.9 nM
F20TH #34 5'-AACUUUUGUGGCUUCACGACCACCAUUUUUGUGUUGUAA-3' Kd=6.1 nM
F20TH #82 5'-CUACUUCAACCACCAGGGAGCAGAUGACUCCAUCAGCAU-3' Kd=6.0 nM
F18TH #11 5'-CACUAAGCAGAUACCGAAAGACUUGCCCGCAACACGCAA-3' Kd ND
F18TH #13 5'-GCGUGGACUGGUCCAUGCACCAUUGACACUUGAUCCACC-3' Kd ND
F18TH #53 5'-UUGCGAAGGAAAAACCGACCUGCUUUACGCGUCAAUAUG-3' Kd=4.5 nM
F18TH #66 5'-ACUAAGAAUUGAUGUGGAUCUGAGUAACACGUACAAUCA-3' Kd ND

Figure 5. In vitro cassette, and sequence of the selected RNA ligands. A) In yttro
cassette. Underlined at the 5'-end is a T7 promoter sequence. The 3'- end is a
PCR primer sequence. B) Sequence of selected RNA ligands.
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Reactions were stopped by addition of, 100 jui 7M urea, TBE [0.0045 IVl TrisBorate, 0.001 M Ethylenediaminetetraacetic acid (EDTA) pH 8.0], containing
0.05% Xylene cyanate, and 0.05% bromophenoi blue, and samples were heated
at 90 °C for three minutes. The samples were then loaded onto a 7M urea, 10%
polyacrylamide gel and the gels were run at 600 volts for 30 minutes. RNA
was located by UV shadowing. RNA was eluted from the gel with two volumes
of 2mM EDTA, and one volume of 3M sodium acetate.

RNA was separated

from gel material by filtration through a 0.22 jum acetate syringe filter. The
filter was washed with 5 volumes of 100% ethanol. Samples were frozen in
liquid nitrogen for 15 minutes, then thawed and the RNA was pelleted by
centrifugation at 13,000 x g for 15 minutes. The pellet was dried by a speed
vacuum and resuspended in DEPC-treated water.

Concentrations were

calculated by the following formula: [RNA] p moles/1 =(1000 x ODggo x dilution
factor X 33)/{320 x92)). Where 1000 is the unit conversion factor to p moles of
RNA, one OD unit is 33 pg/ml, 320 is average molecular weight of a nucleotide
and 92 is the length of the RNA ligand.

PreparaHon of RNA and DNA temptates
PGR amplification.

For preparation of DNA and RNA templates, the PGR

reagents were the same as for SELEX PGR amplifications, except that different
primers and DNA templates were used. These templates were made from the
FIV molecular clone, 34TF10, which contains a cloned provirus of FIV inserted
into the plasmid pUG119 (44). In order to enable synthesis of the RNA template
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a primer designated as 24' with ttie following sequence was used; 5'CCCAGCTTAATACGACTCACTATAGGAGTCC-AGAAGATAAATTACAGG-S'.This
primer contains the promoter for T7 RNA polymerase (underlined), which allowed

in vifro transcription of the PGR product. The other primer used, designated as
#14 was (5'-GGGGTCATAGTATCCTAGTTG-3'). These primers amplified a 316
(corresponding to nt. 2979-3295) base-pair region of the RT encoding region (44).

In vttro transcription of RNA template. In vitro transcriptions were performed
under the same conditions as for in W/ro transcription of SELEX ligands.

Gel purification of RNA template. Gel purification of the RNA template was the
same as used for the purification of SELEX ligands.

Asymmetric PGR amplification for the preparation of DNA template. To prime
the

5'

end

of

the

DNA

a

primer

designated

as

#24

(5'-

CTCCAGAAGATAAATTACAGG-3') was used. Primer #14 concentration was 1/50
that of #24 in order to preferentially amplify only one strand.

Single stranded DNA purification. DNA from asymmetric PGR was purified by
QIAquick spin PGR purification kit (Qiagen, Chatsworth, CA.). This procedure
allows rapid purification with a 90% yield of single stranded or double stranded
DNA PGR products.

Primer annealing.

DNA and RNA templates to be used in RT assays, were
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primed with PCR primer #14. This was done using a Perkin Elmer DNA
thermocycler 410. The primer was added in a 2:1 molar ratio to the respective
templates. The template primer mix was then heated at the following
temperatures; 90 °C for 30 seconds, 60 °C for 15 minutes, 37 °C for 15 minutes,
25 °C for 15 minutes and 4 °C for 15 minutes. All template-primers were stored
at -20 °C until used.

RT assays. RT was assayed essentially as described by North et al (23, 25).
Reactions were carried out in a volume of 50 ji\ which contained 50 mM TrisHCI, pH 8.5, 10 mM dithiothreitol, 0.05% Triton X-100, 250 jug of bovine serum
albumin (nuclease free) per ml, 6 mM MgClg, 80 mM KCI, 20 ^M [Me/hy^-^H]dTTP
[used in reactions with 0.5 Aggo U with poly(rA)-oligo(dT)io, endogenous DNA or
RNA template-primers), or [5'-5-^H]dCTP [used in reactions with 0.5 Ageo U
poly(rl)-oligo(dC )io.i8] and approximately 5 U of RT enzyme. Aliquots of 40 fjl
were taken at the indicated times and spotted onto filters (no. 3, 2.3-cm
diameter; Whatman, Inc., Clifton N.J.) that had been presoaked with 5%
trichloroacetic acid-1% sodium pyrophosphate. Filters were then washed four
times, at least 1 hour each, in ice cold 5% trichloroacetic acid-1% sodium
pyrophosphate and once in 95 % ethanol, dried and counted in liquiflour (Dupont
NEN research products, Boston MA).

Kinetic parameters (Km and Ki) were

determined in reactions with [dTTP] varied from 2.0 to 20 jjM and [template]
varied from 0.5 to 0.012 A260 U. Intercept values calculated from double
reciprocal plot were used to obtain kinetic parameters (22, 24). Values reported
are averages from at least duplicate determinations.
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RESULTS
Initiai screening of the SELEX ligands. SELEX ligands were prepared by in vitro
transcription and gel purification as described in the Material and Methods
section. The ligands were each tested for the ability to inhibit FIV RT, and Ki
values were determined with variable concentrations of dTTP as substrate,
poly(rA)-oligo(dT )io as a template-primer, and purified recombinant FIV RT as
enzyme (Table 3). Two ligands F20 #60 and F18 #53 were potent inhibitors of
FIV RT with Ki values of 108 and 89 nM, respectively. Their structures are shown
in Figure 5. The other five ligands were less inhibitory and had Ki values greater
than 1000 nM. A Lineweaver-Burke plot for inhibition of recombinant FIV RT by
F18 #53 with variable dTTP is shown in Figure 6. All ligands tested were similar
in that they were noncompetitive inhibitors of RT with respect to dTTP.
TABLE 3. Ki DETERMINATIONS FOR SELEX LIGANDS*

SELEX LIGAND

Ki (nM)

F20 #60
F20 #82
F18#11
FIB #13
F18 #53
F18 #66
F18#39

107 ± 18
>1000
>1200
>3200
89 ± 18
>1000
>1000

* Ali experiments were performed with poIy(rA)-oligo(dT)^o used as the templateprimer. Each value represents a mean Ki value with 6 determinations per value.
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Figure 6. Lineweaver-Burke Plot for inhibition of Recombinant FIV RT by SELEX
ligand F18 #53. Concentration of F18 #53 were 200 nM (•) 100 nM (A) 50 (•)
and no inhibitor (•).
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SELEX specificity. All seven SELEX ligands were specific for FIV RT. They did
not inhibit HIV-1 RT (data not shown), and did not bind to AMV and MMLV RTs
(3).

Inhibition of FIV RT by SELEX ligand F18 #53. The SELEX ligand that had the
lowest Ki value, F18 #53 (#53) was further characterized using three different FIV
RTs. These were the purified recombinant RT (which was the enzyme the ligand
was selected with), the purified RT from virions of wild-type FIV, and the RT from
a AZT-resistant FIV, designated as virion-AZR-17c (33). Reactions were carried
out with variable template-primer [poly(rA)-oligo(dT)io] and variable dTTP (Table
4).

Competitive inhibition was seen with variable concentration of template-

primer, and noncompetitive inhibition was observed with variable concentration
of dTTP (Figure 7). Interestingly, the ligand #53 inhibited both wild-type RT and
AZR-17C, (Ki values of 37 and 44 nM respectively) better than the recombinant
RT (Ki value of 89 nM) It is important to note that there was no appreciable
difference, between the AZTTP-resistant RT from AZR-17c and wild-type RT in
susceptibility to this SELEX ligand.

Inhibition of FIV RT by SELEX ligand F20 #60. Ligand F20 #60 (#60) inhibited
purified recombinant FIV RT with a Ki comparable to that of #53. This ligand
was further characterized using variable template-primer (poly(rA)-oligo(dT)io and
purified wild-type-virion FIV RT (Table 5).
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Figure 7. Lineweaver-Burke plots showing modes of inhibition using SELEX
ligand #53. Concentrations of #53 were 200 nM, (À) 50 nM (•) and no #53 (•).
A) Noncompetitive inhibition with variable dTTP concentration and recombinant
FIV RT. B) Competitive inhibition with variable poly(rA)-oligo(dT)io concentration
and recombinant FIV RT.

C) Noncompetitive inhibition with variable dTTP

concentration and wild-type-virion FIV RT. D) Competitive inhibition with variable
poly(rA)-oligo(dT)io concentration and wild-type-virion FIV RT.
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TABLE 4.
Ki DETERMINATIONS FOR INHIBITION OF FIV-RT BY SELEX LIGAND #53*

ENZYME

VARIABLE

Ki (nM) ± SEM

Recombinant FIV RT
Recombinant FIV RT

dTTP
poly(rA)-oligo(dT)io

89 ± 18
95 ± 7

Virion-wild-type FIV RT
Virion-wild-type FIV RT

dTTP
poly(rA)-oligo(dT)io

37 ± 4
31 ± 2

Virion-AZR-17c RT
Virion-AZR-17c RT

dTTP
poly(rA)-oligo(dT)io

44 ± 4
26 ± 7

*AII reactions were run with poly(rA)-oligo(dT)io as a template-primer. Each value
represents a mean Ki value with six determinations per value.

The mode of inhibition is competitive with variable template concentration and
noncompetitive with variable nucleotide concentration (data not shown). In
contrast to #53, #60 inhibited virion-wild-type FIV RT about three fold less than
recombinant FIV RT. Due to the poor inhibition of virion-derived RT, #60 was not
further characterized.

In order to further characterize #53, because of the competitive type of
inhibition with template-primer substrate, a more biologically relevant templateprimer was needed.
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TABLE 5.
Ki DETERMINATIONS FOR INHIBITION OF FIV-RT BY SELEX LIGAND #60*

ENZYME

VARIABLE

Ki (nM) ± SEM

Recombinant FIV RT
Recombinant FIV RT

dTTP
poly(rA)-oligo(dT )io

107 ± 18
120 ± 7

Virion-wild-type FIV RT

dTTP

334 ± 4

* Ali reactionswere run witii poly(rA)-oligo(dT)io as a template-primer. Each value
represents a mean Ki from six determinations.

Construction of an endogenous RNA Template. The RNA template was made by
amplification of a region of the FIV genome from a plasmid containing 34TF10
which has the FIV provirus cloned into pUC119 (44). Primers that amplify a 316
base-pair portion, bases 2979-3295, of the RT-encoding region were used. A T7
RNA polymerase promoter sequence was added at the 5-end of the forward
primer (24') to enable In vitro transcription of the PCR product (Fig 8).

This

provided an RNA template that could be used for RT assays. The primer used for
RT assays with this template was primer #14 which was used for PCR
amplification in the reverse direction.

Under the conditions stated in the Materials and Methods section {"in vitro
transcription of RNA templates") approximately 2680 nmoles of RNA were
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recovered.

The RNA template was then primed with primer #14 (Fig 8) at

various primer-template molar ratios to find the optimal conditionsfor RT activity.
A template:primer ratio of 1:7 gave maximal RT activity (Fig 9 A).

This

template:primer ratio was used in all subsequent RT the assays.

Construction of the DNA Template.

The DNA template was constructed by

asymmetric PGR as described in Materials and Methods.

A typical yield was

2500 nmoles. This template was primed with the PGR primer #14 (Fig 8) and the
optimal template to primer molar ratio for RT activity was determined to be 1:9
(Fig 9 B).

Characterization of reactions with endogenous RNA templates. The velocity of
FIV RT with the endogenous RNA template was first compared to that with poly
(rA)-oligo(dT)io, the standard template primer used for FIV RT assays. The
velocity of FIV RT with the endogenous RNA template was 100 % that of
poly(rA)-oligo(dT )io template (Table 6).

The endogenous RNA template was characterized with AZTTP, ddCTP,
PFA, and ddTTP as inhibitors in RT assays, as described in the Materials and
Methods section. With AZTTP, ddCTP, and ddTTP the mode of inhibition was
competitive with respect
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1. T7 polymerase binding sequence (underlined).
5'-CCCAAGCTTAATACGACTCACTATAGGGAG-3' (25-MER)
3'-GGGTTCGAATTATGCTGAGTGATATCCCTC-5' (TEMPLATE)
2. Sense strand designated as #24.
5'-CTCCACAGATAAATTACAGG-3' (21 MER)
3. Primer 24' with the T7 polymerase binding sequence.
5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-3'(46 MER)
4. An overview of events.
(parent) 5'(primer #14)3'-

CAACTAGGATACTATGACCC-3'
GTTGATCCTATGATACTGGG-5'

5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-3' (primer 24')
3'-GAGGTATCTATTTAATGTGG-5'

Sequence after PGR

5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-CAACTAGGATACTATGACCC-3'
3'-GGGTTCGAATTATGCTGAGTGATATCCCTAGAGGTATCTATTTAATGTGG-GTTGATCCTATGATACTGGG-5'

Fig 8. Design of the genomic FIV RNA template. 1) represents the promoter
sequence for T7 polymerase (underlined). 2) represents the primer (24) 5'-end of
the amplified sequence. 3) represents the sequence of primer 24 with the T7
promoter sequence iigated to its 5'-end (24'). 4) is an overview of events during
PGR amplification.
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to dNTP substrate, as with other homopolymeric template-primers (Fig 10). The
mode of inhibition for PFA was noncompetitive, as it is with homopolymeric
template-primers (Fig 10)(24).

The Michaelis Menton constant. Km for substrate (dTTP) was 2.0 ± 0.1
^M. The inhibition constants, Ki values, for AZTTP, ddTTP, and ddCTP

are

summarized in Table 7. The Ki values were between four-and five-fold higher
than in reactions with homopolymeric RNA template-primers (24).

Characterization of reactions with the DNA template. The velocity of recombinant
FIV RT with the single stranded DNA template-primer was only 13% of that
obtained with poly(rA)-oligo(dT)io (Table 6). These data demonstrate that RT has
a higher activity with the RNA than with a DNA template, at least with this
nucleotide sequence. The DNA and RNA endogenous templates had the same
primer and sequence (except U vs. T in RNA vs. DNA).

The inhibitors used to characterize the DNA template were AZTTP, ddCTP,
ddTTP, and PFA. As found with other template-primers, the mode of inhibition
for AZTTP, ddCTP, and ddTTP is competitive with respect to dNTP substrate (Fig
11). The mode of inhibition for PFA is noncompetitive with respect to dNTP for
the endogenous DNA template (Fig 11).
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TABLE 6. TEMPLATE SPECIFICITIES OF RT ACTIVITIES

TEMPLATE-PRIMER

PERCENT ACTIVITIES*

poly(rA)-oligo(dT)io
poly(rC)-oligo(dG)io
Endogenous RNA Template
Endogenous DNA Template

100
62.2
100
13.2

*100% is 4 pmoles of PH]-dTTP incorporated per hour. Values represent the
mean from two or more determinations. Recombinant FIV RT was used in each
reaction.

TABLE 7. INHIBITION CONSTANTS FOR RT INHIBITORS IN REACTIONS WITH
ENDOGENOUS TEMPLATES.

Ki (nM)*
INHIBITOR

RNA TEMPLATE

DNA TEMPLATE

AZTTP
ddCTP
ddTTP
PFA

56.1 ± 9.0
23.3 ± 5
30.1 ± 0.5
1485 ± 15

90.1 ± 5
58.7 ± 6
21.5 ± 0.5
709 ± 15

* Each Ki value represents the mean value from at least six determinations.
Recombinant FIV RT was used in each reaction.
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Figure 10 Lineweaver-Burke plots for the inhibition of recombinant FIV RT by
nucleotide analogues and PFA In reactions with the endogenous RNA template.
A) Competitive Inhibition by AZTTP: 1000 nM AZTTP (A), 500 nM AZTTP (T),
100 nM AZTTP {•) no AZTTP (•). B) Competitive inhibition by ddCTP: 200 nM
ddCTP (•), 100 nM ddCTP (A), 50 nM ddCTP (•) no ddCTP (•) C) Competitive
inhibition with ddTTP: 500 nM ddTTP (T), 100 nM ddTTP (A), 50 nM ddTTP (•)
no ddTTP (•). D) Noncompetitive Inhibition with PFA: 25 jiiM PFA (T), 10 jiiM
PFA (A), 5 uM PFA (•) no PFA (•).
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Figure 11. Lineweaver-Burke plots for inhibition of the recombinant FIV RT by
nucleotide analogues and PFA in reactions with the endogenous DNA template.
A) Competitive inhibition by AZTTP: 1000 nM AZTTP (T), 500 nM AZTTP (A), 100
nM AZTTP {•) no AZTTP (•).

B) Competitive inhibition by ddCTP: 200 nM

ddCTP (T), 100 nM ddCTP (A), 50 nM ddCTP (•) no ddCTP (•) C) Competitive
inhibition with ddTTP: 500 nM ddTTP (T), 100 nM ddTTP (A), 50 nM ddTTP (•)
no ddTTP (•). D) Noncompetitive inhibition with PFA: 25 jiM PFA (T), 10 ji/M
PFA (A), 5 uM PFA (•) no PFA (•).
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The Michaeiis Menton constant. Km for the endogenous DNA template was 2.0
± 0.1 juM. The inhibition constants, Ki, for AZTTP, ddCTP, and ddTTP are four to
five fold higher than with other DNA template-primers (Table 7) (24).

Inhibition of recombinant FIV RT by SELEX ligand #53
endogenous DNA and RNA template-primers.

in reaction with

SELEX ligand #53 was further

characterized with the endogenous DNA and RNA template-primers. The Ki
values for inhibition of FIV RT by #53 in reactions with those template-primers
are summarized in Table 8. Interestingly, #53 inhibited RT better with the
endogenous templates (45 nM) than with to the homopolymeric templates (95
nM)(Table 4). The modes of inhibition were the same as seen with the
homopolymeric templates, noncompetitive with respectto dTTP, and competitive
with respect to template-primer (Fig 12).
TABLE 8. INHIBITION CONSTANTS FOR LIGAND #53 IN REACTIONS
WITH ENDOGENOUS DNA AND RNA TEMPLATES.

TEMPLATE

VARIABLE

Ki(nM)^

ENDOGENOUS RNA
ENDOGENOUS RNA

ENDOGENOUS RNA
dTTP

45 ± 10
55 ± 5

ENDOGENOUS DNA
ENDOGENOUS DNA

ENDOGENOUS DNA
dTTP

49 ± 8
35 ± 10

* Values represent mean from six or more determinations per value.
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Figure 12. Lineweaver-Burke plots for inhibition of recombinant FIV RT by
SELEX #53 in reactions with endogenous RNA and DNA templates.
Concentrations were 200 nM #53 (•), 100 nM #53 (•), 50 nM #53 (•), and no
#53(#). A) Competitive inhibition in reactions with variable RNA template. B)
Noncompetitive inhibition in reactions with variable dTTP and endogenous RNA
template. C) Competitive inhibition in reactions with variable DNA template. D)
Noncompetitive inhibition in reactions with variable dTTP and endogenous
DNA template.
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DISCUSSION
This study is the first kinetic characterization of the inhibition of RT by
SELEX ligands. It has identified SELEX ligands that are potent inhibitors of
purified FIV RT. Of seven SELEX ligands that were tested, only two ligands,
#53, and #60, were found to be potent inhibitors of FIV RT. These ligands are
comparable in potency to nucleotide inhibitors of FIV RT. AZTTP has a Ki of 54
nM using

recombinant FIV RT, and the endogenous DNA template-primer

where SELEX ligand #53 has a Ki of 45 under the same conditions.

These FIV-RT specific ligands, like the HIV-1 RT-specific RNA ligands
reported by Tuerk et al. (47), were selected in such a way that facilitated but did
not demand a pseudoknot structure. The pseudoknot structure is predicted for
the FIV, and HIV-1 template-primer binding site (4). Interestingly, none of the
FIV RT-specific SELEX ligands formed a psuedoknot. It is possible that some
RNA molecules with pseudoknot structures are in the selected pool; however,
the predominant ligands did not form pseudoknots. The two SELEX ligands that
were identified as potent inhibitors fell into different classes based upon
structure. Ligand #60 has a Class I structure which forms a stem-loop with an
internal bulge. #53 has a class II structure, and also forms a stem-loop with
internal bulge, and contains two U-tracts in the region which is predicted to be
single stranded.

Ligands #53, and #60, share the ability to form a stem-loop

with an internal bulge. This structure may be important for inhibition of FIV RT.
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The other five SELEX ligands were much less inhibitory to FIV RT than
#53 and #60. Interestingly some of the dissociation constants of the other five
ligands are lower than for #53. These data suggest that there is no correlation
between dissociation constants and inhibition constants.

All ligands were

noncompetitive with respect to nucleotide concentration suggesting that they
bind to RT at places other than the nucleotide binding site. Because SELEX
ligands are oligonucleotides, it is not surprising that they compete with the
template-primer, and that they are noncompetitive with respect to nucleotide
concentration. These data (Fig 7, and Table 4) suggest that the #53 and #60
bind to the template-primer site.

All previous kinetic studies of RT with RNA templates, and initial parts of
this work, were done with homopolymer templates. Homopolymeric templates
are adequate for studies with nucleotide analogues which compete with dNTP
substrate.

However, the SELEX ligands compete with template-primer.

Therefore it was desirable to study more biologically relevant, natural templateprimers for further characterization of the ligands.

The templates that were developed included DNA and RNA templates
corresponding to a 316 base-pair fragment of the FIV genome. With these
templates, inhibition of FIV RT by nucleotide analogues and by PFA yielded Ki
values similar to those obtained in reactions with other heteropolymeric DNA
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templates previously used for kinetic characterization of RT Inhibitors (6, 25).
However, the RT activity with heteropolymeric RNA templates used In these
studies was too low for kinetic analyses. RT activity with the endogenous DNA
template-primer used in this study was similar to activity previously reported
with 0X174 and M13 DNA (6).

A few studies of HIV-1 RT have used endogenous templates, but those
studies were focused on aspects of RT other then kinetics of inhibition by
antivirals. Reardon (31) used short template-primers to study the kinetic
mechanism of the RT. These were approximately 50 bases long, primed with a
ten base oligonucleotide.

Other studies with endogenous template-primers

were used in order to study the fidelity of RT (16). These studies used long
templates, approximately 2000-3000 bases in length, in order to study pause
sites and stop sites In the HIV-1 genome (16). The work presented In this thesis
is the first study of inhibition of RT by antivirals with endogenous templates.

Interestingly, SELEX ligand #53 was a more potent inhibitor of FIV RT in
reactions with endogenous templates than with homopolymeric templates.
Inhibition constants from reactions with endogenous templates were about half
of those obtained with the homopolymeric templates. Thus, SELEX ligand #53
should be an even better Inhibitor of viral DNA synthesis than was predicted
with the initial studies with homopolymers. The characterization of SELEX
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ligands with endogenous templates gives insight into how well the ligand may
inhibit FIV replication in cells. However, the template used represents only a
small portion of the FIV genome and the reaction with RT may vary
considerably with sequences from other parts of the genome. Klarman et al.
(16) observed strong pause and stop sites in the HIV-1 genome, and one can
expect similar pause and stop sites in different sequences of the FIV genome.
These sites will affect the enzyme velocity and may alter inhibition kinetics of
SELEX ligands. It will be important to characterize activities of these inhibitors
with template-primer from other parts of the FIV genome.

RT purified from virions of wild-type and AZT-resistant FIV were both
more sensitive than recombinant FIV RT to inhibition by SELEX ligand #53.
This is surprising because the ligand was selected with the recombinant RT.
We do not know the reason for this but it may be due to modifications that
occur during virus replication that do not occur in f, coli.

AZR-17C contains a point mutation at nucleotide 2939 that results in an
amino acid change of a Glu to a Lys at amino acid 202 (33). This mutation in
the FIV RT decreases sensitivity to the active form of AZT, AZTTP. However,
this enzyme remains fully sensitive to inhibition by SELEX ligand #53. This is
not surprising in view of the fact that the mutation responsible for AZT
resistance is in a portion of the RT molecule located below the palm and away
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from the template-primer binding site (as predicted from the crystal structure
of HIV-1 RT and homology of FIV RT to the HIV-1 RT) (18, 44).

It will be

interesting to analyze other drug-resistant mutants, such as those resistant to
ddl or ddC, which have mutations in the template-primer binding domain (2)
with SELEX ligands.

A crucial step in developing SELEX ligands as drugs to use in patients
will be providing a means of delivery. There are several possible ways that an
RNA ligand can be delivered. These include modification of the RNA ligand to
enable cellular uptake and protection from RNases, liposome delivery, and gene
therapy. A problem in RNA modification is the likelihood of structural changes
that may inactivate the ligand.

Liposome delivery is limited by packaging

problems, difficulties in mass production, instability, and problems in selective
delivery (39).

A gene therapy approach seems most promising because in

recent years it has been used for the treatment of adenosine deaminase
deficiency with some success (19). This success was achieved using virus
vectors for delivery and has promoted our collaboration with NeXstar, to
develop a Crandell feline kidney cell (CrFK), which has the DNA sequence to
encode ligand #53 inserted behind strong pol III and pol II promoters within
the vector genome.
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Figure 13. Preliminary data on antiviral activity of SELEX ligand #53 expressed
in CrFK cells. On the X-axis form left to right; CrFK (no ligand), FRT1-1,1-2,1-5,
1-7,1-9 are all CrFk cell lines that express #53 as determined by northern blot
analysis (data not shown), (preliminary results from La Casse, Zhu and North).
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In collaboration with Michael Lochrie of NeXstar we have constructed 36
CrFK cell lines which express ligand #53. Our laboratory has recently shown
that some of these cell are highly protected (99%) from FIV infection (Fig 13).
Our lab is continuing to characterize these cell lines and the antiviral state of
cells expressing the SELEX ligand.

It will be important to use these cell lines that are resistant to infection
by FIV to determine whether mutant FIV that are resistant to SELEX ligand #53
will arise. We predict that resistance will be less frequent than with nucleoside
analogues because of the multiple interaction sites of the ligand with the
enzyme.
If resistance to this ligand does arise, SELEX offers an immediate strategy
to combat it. If a SELEX #53-resistant virus is found, the RT can be purified and
then used for the selection of another SELEX ligand. By alternating the resistant
enzyme and the wild-type enzyme it is conceivable that one can select a ligand
that inhibits both the mutant and the wild-type RT. If further resistance arises
additional ligands can be selected by SELEX. A long term goal will be to
develop a ligand or a set of ligands that will protect against wild-type FIV and
the major resistant mutants.

Results of this study clearly demonstrate that potent inhibitors of FIV RT
can be obtained via the SELEX procedure. The preliminary studies mentioned
above demonstrate that expression of these ligands in cultured feline cells
protects against FIV infection. SELEX offers a promising approach to AIDS
treatment with gene therapy that can be tested in cats.
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